Catalyst Pharmaceutical Partners (CPRX) tumbles, -20% premarket, after announcing a delay in...

|About: Catalyst Pharmaceutical Pa... (CPRX)|By:, SA News Editor

Catalyst Pharmaceutical Partners (CPRX) tumbles, -20% premarket, after announcing a delay in top-line results from a study of its vigabatrin phase II(b) trial for cocaine addiction. The Department of Veterans Affairs Cooperative Studies Program won't be able to provide results around end of month as expected, but the company still expects a report "significantly earlier than we had originally anticipated."